Trial Profile

A randomized, single center study investigating the tolerability of KET01 (ketamine) versus intranasal SPRAVATO (esketamine) spray in healthy male subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Sep 2024 According to Ketabon Media Release, Combined Results from KET01-02 and KET01-03 Trials will be presented as posters at the 37th European College of Neuropsychopharmacology (ECNP) Congress 2024, taking place on September 21-24, 2024 in Milan.
21 May 2024 According to Ketabon GmbH media release, the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach.
17 Nov 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com